Epidemiology and Risk Factors for Isolation of Escherichia Coli Producing CTX-M-type Extended-spectrum β-lactamase in a Large U.S. Medical Center
Overview
Authors
Affiliations
A case-case-control study was conducted to identify independent risk factors for recovery of Escherichia coli strains producing CTX-M-type extended-spectrum β-lactamases (CTX-M E. coli) within a large Southeastern Michigan medical center. Unique cases with isolation of ESBL-producing E. coli from February 2010 through July 2011 were analyzed by PCR for blaCTX-M, blaTEM, and blaSHV genes. Patients with CTX-M E. coli were compared to patients with E. coli strains not producing CTX-M-type ESBLs (non-CTX-M E. coli) and uninfected controls. Of 575 patients with ESBL-producing E. coli, 491 (85.4%) isolates contained a CTX-M ESBL gene. A total of 319 (84.6%) patients with CTX-M E. coli (282 [74.8%] CTX-M-15 type) were compared to 58 (15.4%) non-CTX-M E. coli patients and to uninfected controls. Independent risk factors for CTX-M E. coli isolation compared to non-CTX-M E. coli included male gender, impaired consciousness, H2 blocker use, immunosuppression, and exposure to penicillins and/or trimethoprim-sulfamethoxazole. Compared to uninfected controls, independent risk factors for isolation of CTX-M E. coli included presence of a urinary catheter, previous urinary tract infection, exposure to oxyimino-cephalosporins, dependent functional status, non-home residence, and multiple comorbid conditions. Within 48 h of admission, community-acquired CTX-M E. coli (n = 51 [16%]) and non-CTX-M E coli (n = 11 [19%]) strains were isolated from patients with no recent health care contacts. CTX-M E. coli strains were more resistant to multiple antibiotics than non-CTX-M E. coli strains. CTX-M-encoding genes, especially bla(CTX-M-15) type, represented the most common ESBL determinants from ESBL-producing E. coli, the majority of which were present upon admission. Septic patients with risk factors for isolation of CTX-M E. coli should be empirically treated with appropriate agents. Regional infection control efforts and judicious antibiotic use are needed to control the spread of these organisms.
Heltveit-Olsen S, Gopinathan U, Blix H, Elstrom P, Hoye S J Antimicrob Chemother. 2024; 79(5):1109-1117.
PMID: 38635298 PMC: 11062941. DOI: 10.1093/jac/dkae078.
Maranchick N, Webber J, Alshaer M, Felton T, Peloquin C Antibiotics (Basel). 2023; 12(12).
PMID: 38136730 PMC: 10740680. DOI: 10.3390/antibiotics12121696.
Trautner B, Kaye K, Gupta V, Mulgirigama A, Mitrani-Gold F, Scangarella-Oman N Open Forum Infect Dis. 2023; 9(12):ofac623.
PMID: 37065971 PMC: 10101691. DOI: 10.1093/ofid/ofac623.
Heltveit-Olsen S, Sundvall P, Gunnarsson R, Snaebjornsson Arnljots E, Kowalczyk A, Godycki-Cwirko M BMJ Open. 2022; 12(11):e065217.
PMID: 36319057 PMC: 10098264. DOI: 10.1136/bmjopen-2022-065217.
Mhaya A, Trabelsi R, Aillerie S, Mzali F, Begu D, Tounsi S Antibiotics (Basel). 2022; 11(10).
PMID: 36289987 PMC: 9598323. DOI: 10.3390/antibiotics11101329.